- Home
- WSBF vs LYEL Comparison
WSBF vs LYEL Comparison
Compare WSBF & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBF
- LYEL
- Stock Information
- Founded
- WSBF 1921
- LYEL 2018
- Country
- WSBF United States
- LYEL United States
- Employees
- WSBF N/A
- LYEL N/A
- Industry
- WSBF Savings Institutions
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- WSBF Finance
- LYEL Health Care
- Exchange
- WSBF Nasdaq
- LYEL Nasdaq
- Market Cap
- WSBF 273.1M
- LYEL 253.2M
- IPO Year
- WSBF N/A
- LYEL 2021
- Fundamental
- Price
- WSBF $14.70
- LYEL $16.50
- Analyst Decision
- WSBF
- LYEL Hold
- Analyst Count
- WSBF 0
- LYEL 3
- Target Price
- WSBF N/A
- LYEL $16.67
- AVG Volume (30 Days)
- WSBF 66.6K
- LYEL 47.1K
- Earning Date
- WSBF 10-22-2025
- LYEL 11-06-2025
- Dividend Yield
- WSBF 4.09%
- LYEL N/A
- EPS Growth
- WSBF 82.58
- LYEL N/A
- EPS
- WSBF 1.13
- LYEL N/A
- Revenue
- WSBF $134,196,000.00
- LYEL $60,000.00
- Revenue This Year
- WSBF N/A
- LYEL N/A
- Revenue Next Year
- WSBF N/A
- LYEL N/A
- P/E Ratio
- WSBF $12.93
- LYEL N/A
- Revenue Growth
- WSBF 1.23
- LYEL 11.11
- 52 Week Low
- WSBF $11.61
- LYEL $7.65
- 52 Week High
- WSBF $16.86
- LYEL $30.00
- Technical
- Relative Strength Index (RSI)
- WSBF 42.04
- LYEL 60.15
- Support Level
- WSBF $14.52
- LYEL $15.68
- Resistance Level
- WSBF $15.10
- LYEL $18.08
- Average True Range (ATR)
- WSBF 0.30
- LYEL 1.23
- MACD
- WSBF -0.12
- LYEL -0.11
- Stochastic Oscillator
- WSBF 12.45
- LYEL 45.30
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the Community Banking segment.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.